Lori McMillan - Viveve Medical VP HR
| VIVEDelisted Stock | USD 0.1 0.0005 0.53% |
Insider
Lori McMillan is VP HR of Viveve Medical
| Phone | 720 696 8100 |
| Web | https://www.viveve.com |
Viveve Medical Management Efficiency
The company has return on total asset (ROA) of (0.6213) % which means that it has lost $0.6213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1099) %, meaning that it created substantial loss on money invested by shareholders. Viveve Medical's management efficiency ratios could be used to measure how well Viveve Medical manages its routine affairs as well as how well it operates its assets and liabilities.Viveve Medical currently holds 5.12 M in liabilities with Debt to Equity (D/E) ratio of 1.12, which is about average as compared to similar companies. Viveve Medical has a current ratio of 1.29, suggesting that it may not have the ability to pay its financial obligations when due. Debt can assist Viveve Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Viveve Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viveve Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viveve to invest in growth at high rates of return. When we think about Viveve Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Gina Moss | SINTX Technologies | N/A | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Robert Carlson | Biomerica | N/A | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Hans Boehringer | Biomerica | N/A | |
| Richard Ginn | Tenon Medical | 58 | |
| FACC FESC | Cytosorbents Crp | 53 | |
| Lawrence Picciano | Helius Medical Technologies | N/A | |
| BS MS | SINTX Technologies | N/A | |
| William MD | Nuwellis | N/A | |
| Laurent Duhoux | Nuwellis | N/A | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| CPA CPA | Cytosorbents Crp | 67 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| Mark Knudson | ReShape Lifesciences | 75 | |
| Jonathan Paris | Rapid Micro Biosystems | 48 | |
| Harold MD | NanoVibronix | 70 | |
| MS MS | Cytosorbents Crp | 66 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| CPA CPA | Helius Medical Technologies | 63 | |
| Steven Sloan | Biomerica | 54 | |
Management Performance
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 |
Viveve Medical Leadership Team
Elected by the shareholders, the Viveve Medical's board of directors comprises two types of representatives: Viveve Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viveve. The board's role is to monitor Viveve Medical's management team and ensure that shareholders' interests are well served. Viveve Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viveve Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Robbins, Principal Financial Officer | ||
| Martin PE, Dev Research | ||
| Suzon Lommel, VP Affairs | ||
| Lori McMillan, VP HR | ||
| Scott Durbin, CEO Director | ||
| Deborah MBA, Advisor Director | ||
| Jeannie Swindle, Sr Communications | ||
| Gary Kaiser, VP Marketing | ||
| Jeff Sinclair, VP Sales |
Viveve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viveve Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (3.10) % | ||||
| Current Valuation | 4.26 M | ||||
| Shares Outstanding | 10.72 M | ||||
| Shares Owned By Institutions | 5.21 % | ||||
| Number Of Shares Shorted | 374.24 K | ||||
| Price To Earning | (2.59) X | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 0.66 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Viveve Pink Sheet
If you are still planning to invest in Viveve Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viveve Medical's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |